1 / 19

Everolimus Efficacy Results of Study B253 in De Novo Heart Transplantation

CE-2. Study Objectives Study B253. Primary objective To compare efficacy of everolimus 1.5 and 3.0 mg versus AZA in de novo heart transplant patients in the first 6 months following heart transplantation. 108-3QC. CE-3. Primary Efficacy Endpoint Study B253. Composite efficacy endpoint at 6 months

kenadia
Télécharger la présentation

Everolimus Efficacy Results of Study B253 in De Novo Heart Transplantation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related